非瓣膜性心房颤动患者应用利伐沙班剂量和效果的研究现状概述

Summary of the study on dosage and effect of rivaroxaban in patients with nonvalvular atrial fibrillation

心房颤动是成人常见的心律失常类型,预防心房颤动引起的血栓栓塞事件,是心房颤动治疗策略中重要环节。利伐沙班是口服的Ⅹa因子抑制剂,受食物和其他药物影响小,应用过程中无需常规监测凝血功能,在临床应用广泛。但在临床实践中,无论是一般人群还是肾功能不全、高龄、极端体质量等特殊人群,利伐沙班使用剂量均存在争议,用药过量及用药不足情况普遍存在,临床结局存在差异。因此,本文从利伐沙班在非瓣膜性心房颤动患者中的剂量应用推荐,临床应用现状与效果评价等方面进行文献综述,以期为利伐沙班在非瓣膜性心房颤动患者中的临床应用提供更多的依据,改善非瓣膜性心房颤动患者的预后。

Atrial fibrillation(AF) is a common arrhythmia in adults. Prevention of thromboembolic events caused by AF is an important step in the treatment strategy of AF. Rivaroxaban is an oral factor Ⅹa inhibitor, which is less affected by food and other drugs. There is no need for routine monitoring of coagulation function and it is widely used in clinical. However, in clinical practice, the dosage of rivaroxaban is controversial in both general population and special population such as renal insufficiency, advanced age, extreme weight, etc. Overdosage and underdosage are common, and clinical outcomes are different. Therefore, this paper reviewed literatures from the aspects of dose recommendation, clinical application status and effect evaluation of rivaroxaban in patients with nonvalvular atrial fibrillation(NVAF), in order to provide more evidence for the clinical application of rivaroxaban and improve the prognosis of patients with NVAF.